Mnogofaktornoe upravlenie sakharnym diabetom 2 tipa: kakovy nashi segodnyashnie vozmozhnosti


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents data of published meta-analyses and systematic reviews on the effectiveness and safety of therapy with incretins, and the results of the combined measures of DM outcomes using different therapeutic approaches.

Full Text

Restricted Access

About the authors

G. R Galstyan

References

  1. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289(1):76-9.
  2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet 1998;352(9131):837-53.
  3. Stratton I.M., Adler Al., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321(7258):405-12.
  4. Patel A, MacMahon S., Chalmers J., et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358(24):2560-72.
  5. Duckworth W., Abraira C., Moritz T., et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39.
  6. Gerstein H.C., Miller M.E., Byington R.P. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59.
  7. Buse J.B., Ginsberg H.N., Bakris G.L., et al; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30(1):162-72.
  8. Pi-Sunyer X., Blackburn G., Brancati F.L., et al; Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007;30(6):1374-83.
  9. Goldenberg R.M. Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents. Canadian Journal of Diabetes 2011;35(5):518-27.
  10. Bennetti W.L., Maruthur N.M., Singh S., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-13.
  11. Russell-Jones D., Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799-812.
  12. ADA. Standards of medical care in diabetes, 2009. Diabetes Care 2009;32(Suppl. 1): 13-61.
  13. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists /American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
  14. DeFronzo R.A. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 2010;123:38-48.
  15. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
  16. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193-203.
  17. Schernthaner G., Barnett A.H., Betteridge D.J., et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010;53:1258-69.
  18. Nauck M.A. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011;124(1):3-18.
  19. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. AACE/ACE diabetes algorithm for glycemic control, 2009 [article on-line]. Available from https://www.aace.com/sites/default/files/ GlycemicControlAlgorithm.pdf. Accessed 17 November 2011.
  20. Marre M., Shaw J., Brandle M., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
  21. Nauck M.A., Frid A., Hermansen K., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009; 32:84-90.
  22. Garber A., Henry R., Ratner R., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81.
  23. Zinman B., Gerich J., Buse J.B., et al. Efficacy and safety of the human GLP-1 analogue liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30.
  24. Russell-Jones D., Vaag A., Schmitz O., et al. On behalf of the LEAD-5 met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 2009;52:2046-55.
  25. Buse J.B., Rosenstock J., Sesti G., et al; for the LEAD Study Group. A study of two glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomised, 26-week, open-label trial (LEAD-6). Lancet 2009;374:39-47.
  26. Pratley R.E., Nauck M., Bailey T., et al; for the 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin in patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56.
  27. Nauck M.A., Vaag A., Colagiuri S., et al. HbA1c reduction with liraglutide in type 2 diabetes patients is associated with initial HbA1c levels. International Diabetes Federation - 20th World Diabetes Congress 2009;1400.
  28. Henry R.R., Buse J.B., Sesti G., et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A1c: a meta-analysis of the liraglutide development program. Endocr Pract 2011;17(6):906-13.
  29. Holst J.J., Nauck M., Brett J., Falahati A., Pratley R. Improvement in glycaemic control when adding liraglutide to existing therapy: results from a meta-analysis of six large randomised clinical trials. Diabetologia 2009;52(1) :288.
  30. Buse J.B., Sesti G., Schmidt W.E., et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes care, 2010; 33(6):1300-303
  31. Pratley R.E. et al. Diabetes 2011: 60(1):1119-P.
  32. Fakhoury W.K., Lereun C., Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86:44-57.
  33. Reid T. Choosing GLP-1 receptor agonists or DPP-4 inhibitors: weighing the clinical trial evidence. Clinical diabetes 2012;30(1):3-12.
  34. Meneghini L.F., Orozco-Beltran D., Khunti K., Caputo S., et al. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 2011;96(11):3337-53.
  35. Ismail M.H. Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic. Am J MedSci 2011;341:485-92.
  36. Vilsb ll T., Christensen M., Junker A.E., et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and metaanalyses of randomised controlled trials. BMJ 2012;344:d7771 doi: 10.1136/bmj.d7771 (Published 11 January 2012).
  37. Gilbert M.P., Pratley R.E. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. The American Journal of Medicine 2009;122(6A):11-24.
  38. Zinman B., Colagiuri S., Madsbad S., et al. The human GLP-1 analog, liraglutide, improves BMI and waist circumference in patients with type 2 diabetes: meta-analysis of six phase 3 trials. Diabetes 2010;59(Suppl. 1): A495 (1894-P).
  39. Karagiannis T., Paschos P., Paletas K., et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369 doi: 10.1136/bmj.e1369 (Published 12 March 2012).
  40. Repas T. Next generetion GLP-1 therapy: an introduction to liraglutide. Postgraduate Madicine 2011;123(5):239-47.
  41. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patient with hypertension: principal results of Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;35(9118): 1755-62.
  42. Patel A. ADVANCE Collaborative Group, MacMahon S, et al. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomice controlled trial. Lancet 2007;370(9590):829-40.
  43. Fonseca V., Madsbad S., Falahati A., et al. Once daily human GLP-1 analog liraglutide reduces systolic blood pressure: a metaanalysis of six clinical trials (LEAD). Diabetes 2009;58(1):A146.
  44. Zinman B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? The American Journal of Medicine 2011; 124:19-34.
  45. Zinman B., Schmidt W.E., Moses A., et al. Achieving a clinically relevant composite outcome of an HbA1c of №7 % without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes, Obesity and Metabolism 2011;doi:10.1111/ j.1463-1326.2011.01493.x.
  46. Zinman B., Buse J,, Falahati A., et al. Liraglutide more effectively achieves a composite endpoint for A1C, SBP and weight change than other diabetes therapies. Diabetes 2009;58(Suppl. 1):A143.
  47. Garber A. Incretin effects on b-cell function, replication, and mass. Diabetes care 2011;34(2):258-63.
  48. Noel R.A., Braun D.K., Patterson R.E., Bloomgren G.L. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32(5):834-38.
  49. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (5-й выпуск) / Под ред. И.И. Дедова, М.В. Шестаковой. М., 2011: 116 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies